Can the 2019 Novel Coronavirus Cause Parkinson's Disease?

Achbani, Abderrahmane; Sine, Hasnaa; Naciri, Aziz; Baba, Mohamed Amine; Kharbach, Ahmed; Bouchriti, Youssef; Nejmeddine, Mohamed

doi:10.1002/mds.28118

Cited by 21 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some literature has already highlighted potential links between COVID-19 virus and neurodegenerative conditions, including suggestions regarding PD 104,112 . These are based on multiple observations:…”

Section: Covid-19 and The Possibility Of A Post-viral Parkinsonism: Cmentioning

confidence: 99%

COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside

Sulzer

Antonini

Leta

et al. 2020

npj Parkinsons Dis.

145

165

View full text Add to dashboard Cite

This Viewpoint discusses insights from basic science and clinical perspectives on coronavirus disease 2019 (COVID-19)/severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection in the brain, with a particular focus on Parkinson's disease. Major points include that neuropathology studies have not answered the central issue of whether the virus enters central nervous system neurons, astrocytes or microglia, and the brain vascular cell types that express virus have not yet been identified. Currently, there is no clear evidence for human neuronal or astrocyte expression of angiotensin-converting enzyme 2 (ACE2), the major receptor for viral entry, but ACE2 expression may be activated by inflammation, and a comparison of healthy and infected brains is important. In contrast to the 1918 influenza pandemic and avian flu, reports of encephalopathy in COVID-19 have been slow to emerge, and there are so far no documented reports of parkinsonism apart from a single case report. We recommend consensus guidelines for the clinical treatment of Parkinson's patients with COVID-19. While a role for the virus in causing or exacerbating Parkinson's disease appears unlikely at this time, aggravation of specific motor and non-motor symptoms has been reported, and it will be important to monitor subjects after recovery, particularly for those with persisting hyposmia.

show abstract

Section: Covid-19 and The Possibility Of A Post-viral Parkinsonism: Cmentioning

confidence: 99%

COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside

Sulzer

Antonini

Leta

et al. 2020

npj Parkinsons Dis.

145

165

View full text Add to dashboard Cite

show abstract

“…In another study in Italy, PD patients exhibited substantial deterioration in motor and non-motor symptoms during mild-moderate SARS-CoV-2 infection as compared to COVID-19-negative PD patients [35]. Emerging evidence revealed that SARS-CoV-2 infection often develops parkinsonism [4]. Several hypotheses have been proposed in this regard.…”

Section: Covid-19 In Parkinson's Diseasementioning

confidence: 99%

Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic

et al. 2021

View full text Add to dashboard Cite

The unremitting coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) marked a year-long phase of public health adversaries and has severely compromised healthcare globally. Early evidence of COVID-19 noted its impact on the pulmonary and cardiovascular functions, while multiple studies in recent time shed light on its substantial neurological complications, though a comprehensive understanding of the cause(s), the mechanism(s), and their neuropathological outcomes is scarce. In the present review, we conferred evidence of neurological complications in COVID-19 patients and shed light on the SARS-CoV-2 infection routes including the hematogenous, direct/neuronal, lymphatic tissue or cerebrospinal fluid, or infiltration through infected immune cells, while the underlying mechanism of SARS-CoV-2 invasion to the central nervous system (CNS) was also discussed. In an up-to-date manner, we further reviewed the impact of COVID-19 in developing diverse neurologic manifestations associated with CNS, peripheral nervous system (PNS), skeletal muscle, and also pre-existing neurological diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and myasthenia gravis. Furthermore, we discussed the involvement of key factors including age, sex, comorbidity, and disease severity in exacerbating the neurologic manifestations in COVID-19 patients. An outlook of present therapeutic strategies and state of existing challenges in COVID-19 management was also accessed. Conclusively, the present report provides a comprehensive review of COVID-19-related neurological complications and emphasizes the need for their early clinical management in the ongoing COVID-19 pandemic. Keywords COVID-19 • SARS-CoV-2 • CNS • PNS • Neuroinvasion • COVID-19 pandemic • Neurological complications Highlights• Coronavirus disease 2019 (COVID-19)-associated complications involve substantial neurological manifestations.• SARS-CoV-2 infection routes include the hematogenous, neuronal, lymphatic tissue/cerebrospinal fluid, or infiltration through infected immune cells.• COVID-19 promotes neurologic manifestations associated with the central and peripheral nervous system and exacerbates the pre-existing neurological and neurodegenerative conditions. • Patient's age, sex, comorbidity, and severity of the infection are key factors that determine the extent of neurologic manifestations in COVID-19 patients.

show abstract

“…Angiotensin-converting enzyme 2 is also highly expressed in dopaminergic neurons. Although the expression levels of ACE2 in the brain of PD patients is decreased due to degeneration and loss of dopaminergic neurons, there are still evidences that SARS-CoV-2 can invade CNS of PD patients and further aggravate the CNS injury and clinical situations (Achbani et al, 2020;Pavel et al, 2020;Victorino et al, 2020). Recently, the first case of encephalopathic complications in a 74-year-old PD patient infected with SARS-CoV-2 was reported (Filatov et al, 2020).…”

Section: Covid-19 and Parkinson's Diseasementioning

confidence: 99%

Impact of COVID-19 Pandemic on Patients With Neurodegenerative Diseases

Chen

Dong

2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

COVID-19 pandemic has already produced great impacts on global health security and social-economy. Elderly, particularly those with underlying diseases, are suffering from higher fatality rate. Neurodegenerative diseases are a group of incurable neurological disorders of loss of neuron and/or myelin sheath, which affect hundreds of millions of elderly populations and usually need long-term care. Older population is one of the most vulnerable to COVID-19 pandemic. In this report, we reviewed the current status of COVID-19 on the patients with several neurodegenerative diseases, particularly Alzheimer’s disease, Parkinson’s disease, prion disease, and amyotrophic lateral sclerosis. Meanwhile, the potential mechanisms of SARS-CoV-2 infection in the pathogenesis of neurodegenerative diseases were also summarized.

show abstract

Can the 2019 Novel Coronavirus Cause Parkinson's Disease?

Cited by 21 publications

References 7 publications

COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside

COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside

Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic

Impact of COVID-19 Pandemic on Patients With Neurodegenerative Diseases

Contact Info

Product

Resources

About